Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Biogen Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Biogen Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Biogen Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income attributable to Biogen Inc.1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 3, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 1, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 2, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 3, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 4, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 3, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 4, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 3, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Biogen Inc. Annual Report.
The analysis of the financial data reveals several notable trends across the periods observed.
- Share Price
- The share price generally demonstrated a strong upward trend from 2006 through 2015, rising from $45.50 to a peak of $391.12 in 2015. This represents a significant appreciation over this period. However, after 2015, the share price exhibited a declining pattern, dropping notably to $220.17 by 2022. Despite some fluctuations, the overall trend after 2015 was downward, reflecting potential challenges or changing market perceptions.
- Earnings Per Share (EPS)
- The EPS showed a consistent growth trajectory from 2006 through 2020, increasing from $0.47 to a high of $33.83 in 2020. This steady increase suggests improving profitability and operational efficiency during this timeframe. After 2020, EPS declined substantially to $10.59 in 2022, indicating a significant reduction in earnings performance in the most recent years, which may warrant further investigation to understand underlying factors.
- Price-to-Earnings (P/E) Ratio
- The P/E ratio displayed considerable volatility across the years. Early on, it decreased from a high of 97.42 in 2006 to a more moderate range between approximately 15 and 30 in the subsequent years. The ratio peaked again at 38.21 in 2014 before declining to below 10 by 2020, suggesting that the market priced earnings more conservatively in later years despite strong EPS growth. Following 2020, the P/E ratio increased again to 20.79 by 2022, likely reflecting the sharp EPS decline combined with relative share price movements.
In summary, the data reflects a period of robust growth in both share price and earnings until about 2015–2020, followed by a marked decrease in both metrics in the latest years. The fluctuating P/E ratio suggests changing investor sentiment and valuation dynamics, possibly influenced by market conditions, company performance changes, or sector-specific developments.
Comparison to Competitors
Biogen Inc., P/E, long-term trends, comparison to competitors
| Biogen Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2022 | |||||||||||||
| Feb 3, 2021 | |||||||||||||
| Feb 6, 2020 | |||||||||||||
| Feb 6, 2019 | |||||||||||||
| Feb 1, 2018 | |||||||||||||
| Feb 2, 2017 | |||||||||||||
| Feb 3, 2016 | |||||||||||||
| Feb 4, 2015 | |||||||||||||
| Feb 6, 2014 | |||||||||||||
| Feb 5, 2013 | |||||||||||||
| Feb 3, 2012 | |||||||||||||
| Feb 4, 2011 | |||||||||||||
| Feb 9, 2010 | |||||||||||||
| Feb 6, 2009 | |||||||||||||
| Feb 14, 2008 | |||||||||||||
| Feb 21, 2007 | |||||||||||||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Biogen Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Biogen Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 3, 2022 | ||
| Feb 3, 2021 | ||
| Feb 6, 2020 | ||
| Feb 6, 2019 | ||
| Feb 1, 2018 | ||
| Feb 2, 2017 | ||
| Feb 3, 2016 | ||
| Feb 4, 2015 | ||
| Feb 6, 2014 | ||
| Feb 5, 2013 | ||
| Feb 3, 2012 | ||
| Feb 4, 2011 | ||
| Feb 9, 2010 | ||
| Feb 6, 2009 | ||
| Feb 14, 2008 | ||
| Feb 21, 2007 | ||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Biogen Inc., P/E, long-term trends, comparison to industry (health care)
| Biogen Inc. | Health Care | |
|---|---|---|
| Feb 3, 2022 | ||
| Feb 3, 2021 | ||
| Feb 6, 2020 | ||
| Feb 6, 2019 | ||
| Feb 1, 2018 | ||
| Feb 2, 2017 | ||
| Feb 3, 2016 | ||
| Feb 4, 2015 | ||
| Feb 6, 2014 | ||
| Feb 5, 2013 | ||
| Feb 3, 2012 | ||
| Feb 4, 2011 | ||
| Feb 9, 2010 | ||
| Feb 6, 2009 | ||
| Feb 14, 2008 | ||
| Feb 21, 2007 | ||
| Mar 3, 2006 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).